<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632994</url>
  </required_header>
  <id_info>
    <org_study_id>16161</org_study_id>
    <secondary_id>I8I-MC-JYAA</secondary_id>
    <nct_id>NCT02632994</nct_id>
  </id_info>
  <brief_title>Master Rollover Protocol for Continued Safety Assessment of Study Drug</brief_title>
  <official_title>Master Rollover Protocol for Continued Safety Assessment of Study Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      This study is for patients who have participated in a previous study and who continue to&#xD;
      receive benefit to have continued access to study drug and/or treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2503029</intervention_name>
    <description>Administered orally.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Administered orally.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be eligible patients must be currently receiving benefit in a concluded Lilly study&#xD;
             for a compound that has opened an addendum in the continued access protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not be concurrently enrolled in any other type of medical research&#xD;
             judged not to be scientifically or medically compatible with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>310-325-8252</phone>
    </contact>
    <investigator>
      <last_name>Dr. Parvin Fatheddin Peddi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>260-436-0800</phone>
    </contact>
    <investigator>
      <last_name>Dr. Sunil Babu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Dr. Howard A. Burris III</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

